Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 168

1.

FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors.

Cremasco V, Astarita JL, Grauel AL, Keerthivasan S, MacIsaac KD, Woodruff MC, Wu M, Spel L, Santoro S, Amoozgar Z, Laszewski T, Cruz-Migoni S, Knoblich K, Fletcher AL, LaFleur M, Wucherpfennig KW, Pure E, Dranoff G, Carroll M, Turley SJ.

Cancer Immunol Res. 2018 Sep 28. pii: canimm.0098.2018. doi: 10.1158/2326-6066.CIR-18-0098. [Epub ahead of print]

PMID:
30266714
2.

Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity.

Ito Y, Ashenberg O, Pyrdol J, Luoma AM, Rozenblatt-Rosen O, Hofree M, Christian E, Ferrari de Andrade L, Tay RE, Teyton L, Regev A, Dougan SK, Wucherpfennig KW.

J Exp Med. 2018 Oct 1;215(10):2617-2635. doi: 10.1084/jem.20180300. Epub 2018 Sep 5.

PMID:
30185635
3.

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS.

Nat Med. 2018 Oct;24(10):1550-1558. doi: 10.1038/s41591-018-0136-1. Epub 2018 Aug 20.

PMID:
30127393
4.

Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells.

Kim YC, Zhang AH, Yoon J, Culp WE, Lees JR, Wucherpfennig KW, Scott DW.

J Autoimmun. 2018 Aug;92:77-86. doi: 10.1016/j.jaut.2018.05.003. Epub 2018 May 30.

PMID:
29857928
5.

Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses.

Clark LE, Mahmutovic S, Raymond DD, Dilanyan T, Koma T, Manning JT, Shankar S, Levis SC, Briggiler AM, Enria DA, Wucherpfennig KW, Paessler S, Abraham J.

Nat Commun. 2018 May 14;9(1):1884. doi: 10.1038/s41467-018-04271-z.

6.

Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq.

Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, Haberler C, Yizhak K, Gojo J, Egervari K, Mount C, van Galen P, Bonal DM, Nguyen QD, Beck A, Sinai C, Czech T, Dorfer C, Goumnerova L, Lavarino C, Carcaboso AM, Mora J, Mylvaganam R, Luo CC, Peyrl A, Popović M, Azizi A, Batchelor TT, Frosch MP, Martinez-Lage M, Kieran MW, Bandopadhayay P, Beroukhim R, Fritsch G, Getz G, Rozenblatt-Rosen O, Wucherpfennig KW, Louis DN, Monje M, Slavc I, Ligon KL, Golub TR, Regev A, Bernstein BE, Suvà ML.

Science. 2018 Apr 20;360(6386):331-335. doi: 10.1126/science.aao4750.

PMID:
29674595
7.

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.

Ferrari de Andrade L, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF Jr, Harvey CJ, Kobold S, Pyrdol JW, Yoon C, Yuan GC, Hodi FS, Dranoff G, Wucherpfennig KW.

Science. 2018 Mar 30;359(6383):1537-1542. doi: 10.1126/science.aao0505.

PMID:
29599246
8.

Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ.

Nature. 2018 Mar 14;555(7696):402. doi: 10.1038/nature25145.

9.

A facile approach to enhance antigen response for personalized cancer vaccination.

Li AW, Sobral MC, Badrinath S, Choi Y, Graveline A, Stafford AG, Weaver JC, Dellacherie MO, Shih TY, Ali OA, Kim J, Wucherpfennig KW, Mooney DJ.

Nat Mater. 2018 Jun;17(6):528-534. doi: 10.1038/s41563-018-0028-2. Epub 2018 Mar 5.

10.

Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses.

Choi IK, Wang Z, Ke Q, Hong M, Qian Y, Zhao X, Liu Y, Kim HJ, Ritz J, Cantor H, Rajewsky K, Wucherpfennig KW, Zhang B.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E686-E695. doi: 10.1073/pnas.1713607115. Epub 2018 Jan 8.

11.

A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P, Long HW, Yuan GC, Doench J, Brown M, Liu XS, Wucherpfennig KW.

Science. 2018 Feb 16;359(6377):770-775. doi: 10.1126/science.aao1710. Epub 2018 Jan 4.

12.

Immunotherapy for glioblastoma: on the sidelines or in the game?

Reardon DA, Wucherpfennig K, Chiocca EA.

Discov Med. 2017 Nov;24(133):201-208. Review.

13.

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.

Schmid D, Park CG, Hartl CA, Subedi N, Cartwright AN, Puerto RB, Zheng Y, Maiarana J, Freeman GJ, Wucherpfennig KW, Irvine DJ, Goldberg MS.

Nat Commun. 2017 Nov 23;8(1):1747. doi: 10.1038/s41467-017-01830-8.

14.

Erratum: The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection.

Moffett HF, Cartwright ANR, Kim HJ, Godec J, Pyrdol J, Äijö T, Martinez GJ, Rao A, Lu J, Golub TR, Cantor H, Sharpe AH, Novina CD, Wucherpfennig KW.

Nat Immunol. 2017 Sep 19;18(10):1173. doi: 10.1038/ni1017-1173d. No abstract available.

PMID:
28926530
15.

An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ.

Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5. Erratum in: Nature. 2018 Mar 14;555(7696):402.

16.

The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection.

Moffett HF, Cartwright ANR, Kim HJ, Godec J, Pyrdol J, Äijö T, Martinez GJ, Rao A, Lu J, Golub TR, Cantor H, Sharpe AH, Novina CD, Wucherpfennig KW.

Nat Immunol. 2017 Jul;18(7):791-799. doi: 10.1038/ni.3755. Epub 2017 May 22. Erratum in: Nat Immunol. 2017 Sep 19;18(10 ):1173.

17.

Immunomodulation for glioblastoma.

Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH.

Curr Opin Neurol. 2017 Jun;30(3):361-369. doi: 10.1097/WCO.0000000000000451. Review.

PMID:
28368867
18.

Studying Dynamic Plasma Membrane Binding of TCR-CD3 Chains During Immunological Synapse Formation Using Donor-Quenching FRET and FLIM-FRET.

Gagnon E, Connolly A, Dobbins J, Wucherpfennig KW.

Methods Mol Biol. 2017;1584:259-289. doi: 10.1007/978-1-4939-6881-7_16.

PMID:
28255707
19.

Noninvasive Imaging of Human Immune Responses in a Human Xenograft Model of Graft-Versus-Host Disease.

Van Elssen CHMJ, Rashidian M, Vrbanac V, Wucherpfennig KW, Habre ZE, Sticht J, Freund C, Jacobsen JT, Cragnolini J, Ingram J, Plaisier L, Spierings E, Tager AM, Ploegh HL.

J Nucl Med. 2017 Jun;58(6):1003-1008. doi: 10.2967/jnumed.116.186007. Epub 2017 Feb 16.

20.

Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation.

Verbeke CS, Gordo S, Schubert DA, Lewin SA, Desai RM, Dobbins J, Wucherpfennig KW, Mooney DJ.

Adv Healthc Mater. 2017 Mar;6(6). doi: 10.1002/adhm.201600773. Epub 2017 Jan 24.

Supplemental Content

Loading ...
Support Center